Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824)

Rafael Baptista, David M. Fazakerley, Manfred Beckmann, Les Baillie, Luis A. J. Mur

Research output: Contribution to journalArticlepeer-review

77 Citations (SciVal)
185 Downloads (Pure)

Abstract

Pretomanid is a promising anti-tubercular drug currently at clinical phase III, but its mechanisms of action are currently unclear. This study aimed to: (i) reveal the metabolome of Mycobacterium smegmatis under pretomanid treatment; (ii) compare major sources of metabolite variation in bacteria treated with pretomanid treatment and other antibiotics; and (iii) to target metabolites responsible for the killing activity of pretomanid in mycobacteria. Untargeted high-resolution metabolite profiling was carried out using flow infusion electrospray ion high resolution mass spectrometry (FIE-HRMS) to identify and quantify metabolites. The identification of key metabolites was independently confirmed by gas-chromatography time-of flight mass spectrometry (GC-tofMS) in comparison to standards. Pretomanid treatments generated a unique distinctive metabolite profile when compared to ampicillin, ethambutol, ethionamide, isoniazid, kanamycin, linezolid, rifampicin and streptomycin. Metabolites which differed significantly only with pretomanid treatment were identified and mapped on to bacterial metabolic pathways. This targeted the pentose phosphate pathway with significant accumulation seen with fructose-6-phosphate, ribose-5-phosphate and glyceraldehyde-3-phosphate. These effects were linked to the accumulation of a toxic metabolite methylglyoxal. This compound showed significant antimicrobial activity (MIC 0.65 mM) against M. smegmatis.
Original languageEnglish
Article number5084
Number of pages7
JournalScientific Reports
Volume8
Issue number1
Early online date23 Mar 2018
DOIs
Publication statusE-pub ahead of print - 23 Mar 2018

Keywords

  • Humanities and Social Sciences
  • Science
  • multidisciplinary

Fingerprint

Dive into the research topics of 'Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824)'. Together they form a unique fingerprint.

Cite this